trending Market Intelligence /marketintelligence/en/news-insights/trending/hnS4dC-ITdLNQ6d37B8AYQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Cerecor sells depression drug to Janssen Pharmaceuticals

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Cerecor sells depression drug to Janssen Pharmaceuticals

Cerecor Inc. sold all rights for CERC-501 to Johnson & Johnson's Janssen Pharmaceuticals Inc. for initial gross proceeds of $25 million.

Of the gross proceeds, $3.75 million was deposited into a 12-month escrow to secure future indemnification obligations to Janssen, as well as a potential future $20 million regulatory milestone payment.

CERC-501 is an oral kappa opioid receptor antagonist being developed to treat major depressive disorder and substance use disorders.

Janssen Pharmaceuticals will now be responsible for the drug's ongoing clinical trials as well as new development and commercialization.